JP4801802B2 - 特定の選択的な電気信号および電磁信号によって生成される電場の印加を介して骨細胞における骨形成タンパク質(bmp)遺伝子発現を上方制御するシステムおよび方法 - Google Patents
特定の選択的な電気信号および電磁信号によって生成される電場の印加を介して骨細胞における骨形成タンパク質(bmp)遺伝子発現を上方制御するシステムおよび方法 Download PDFInfo
- Publication number
- JP4801802B2 JP4801802B2 JP2006549515A JP2006549515A JP4801802B2 JP 4801802 B2 JP4801802 B2 JP 4801802B2 JP 2006549515 A JP2006549515 A JP 2006549515A JP 2006549515 A JP2006549515 A JP 2006549515A JP 4801802 B2 JP4801802 B2 JP 4801802B2
- Authority
- JP
- Japan
- Prior art keywords
- bone
- bmp
- electric field
- signal
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000005684 electric field Effects 0.000 title claims description 73
- 230000014509 gene expression Effects 0.000 title claims description 64
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 title claims description 32
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 title claims description 31
- 229940112869 bone morphogenetic protein Drugs 0.000 title claims description 31
- 210000002449 bone cell Anatomy 0.000 title description 21
- 238000000034 method Methods 0.000 title description 21
- 210000000988 bone and bone Anatomy 0.000 claims description 50
- 210000001519 tissue Anatomy 0.000 claims description 34
- 206010017076 Fracture Diseases 0.000 claims description 28
- 230000008878 coupling Effects 0.000 claims description 25
- 238000010168 coupling process Methods 0.000 claims description 25
- 238000005859 coupling reaction Methods 0.000 claims description 25
- 208000010392 Bone Fractures Diseases 0.000 claims description 12
- 208000001132 Osteoporosis Diseases 0.000 claims description 12
- 230000035876 healing Effects 0.000 claims description 8
- 206010031264 Osteonecrosis Diseases 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000007547 defect Effects 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 25
- 238000011282 treatment Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 16
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 15
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 15
- 230000005672 electromagnetic field Effects 0.000 description 15
- 241000906034 Orthops Species 0.000 description 14
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 10
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 10
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 10
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 9
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 9
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 9
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 3
- 108010041952 Calmodulin Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000003491 cAMP production Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000035194 endochondral ossification Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000000513 rotator cuff Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000003351 stiffener Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000027502 Ankle fracture Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241001441571 Hiodontidae Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000357292 Monodactylus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010041541 Spinal compression fracture Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002229 photoelectron microspectroscopy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
本発明は、以下の実施例において実証されるものであるが、この実施例は例示を目的とし、本発明の範囲を限定することを意図するものではない。
MC3T3−E1骨細胞(5×105細胞/cm2)を、特別改良したCooperディッシュ上で平板培養した。前記細胞を培地で7日間増殖させ、この培地を実験条件を開始する直前に交換した。これらの研究全般における実験用細胞培養は、60kHz、静電結合型の正弦波、44.81ピーク−ピークの出力振幅を伴う電場の条件下に置いた。前記条件により、前記ディッシュの培地に、電流密度が300μA/cm2で20mV/cmの算出電場強度を発生させた。対照細胞培養ディッシュは、電極が関数発生器に接続されていない点を除いては、刺激を受けた細胞培養ディッシュと同一であった。
Claims (6)
- 骨折、骨折の危険性のある骨、遷延治癒骨折、骨折の癒着不能、骨欠損症、脊椎固定、骨壊死、および骨粗鬆症のうちの少なくとも1つを治療する装置であって、
周波数60kHzの特定且つ選択的な信号を少なくとも1つ生成する信号源と、
前記信号源に接続され、前記少なくとも1つの特定且つ選択的な信号を受信するものであり、且つ標的組織に対して作用可能に配置された電場生成手段と
を有し、
前記電場生成手段は、前記少なくとも1つの特定且つ選択的な信号を受信して20mV/cmの振幅の電場を前記標的組織に発生させ、当該振幅は、骨形成タンパク質の遺伝子発現を前記標的組織において上方制御させる特定且つ選択的な振幅であり、
前記信号源は、前記少なくとも1つの特定且つ選択的な信号を1分間オンおよび1分間オフの間隔の50%のデューティサイクルで24時間毎に24時間の間印加して、骨形成タンパク質の遺伝子発現を前記標的組織において選択的に上方制御させるものである
装置。 - 請求項1記載の装置において、さらに、
前記信号源を駆動する携帯用電源装置を有するものである装置。 - 請求項1記載の装置において、さらに、
前記電場生成手段を患者の身体の骨組織の近傍に取着する手段を有するものである装置。 - 請求項1記載の装置において、さらに、
前記信号源を前記患者の身体に取着する手段を有するものである装置。 - 請求項1記載の装置において、前記少なくとも1つの特定且つ選択的な信号を前記電場生成手段に印加することによって生成される前記電場は、静電結合および誘導結合のうちの1つを介して前記標的組織に印加されるものである装置。
- 請求項1記載の装置において、前記特定且つ選択的な信号は正弦波形を有するものである装置。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53575504P | 2004-01-12 | 2004-01-12 | |
US60/535,755 | 2004-01-12 | ||
PCT/US2005/000793 WO2005070136A2 (en) | 2004-01-12 | 2005-01-11 | Up-regulation of bone morphogenetic protein (bmp) gene expression in bone cells by electromagnetic signals |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007517624A JP2007517624A (ja) | 2007-07-05 |
JP2007517624A5 JP2007517624A5 (ja) | 2008-03-06 |
JP4801802B2 true JP4801802B2 (ja) | 2011-10-26 |
Family
ID=34806961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006549515A Expired - Lifetime JP4801802B2 (ja) | 2004-01-12 | 2005-01-11 | 特定の選択的な電気信号および電磁信号によって生成される電場の印加を介して骨細胞における骨形成タンパク質(bmp)遺伝子発現を上方制御するシステムおよび方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8017369B2 (ja) |
EP (1) | EP1716228A4 (ja) |
JP (1) | JP4801802B2 (ja) |
KR (1) | KR101324824B1 (ja) |
CN (1) | CN1918285B (ja) |
AU (1) | AU2005206794B2 (ja) |
BR (1) | BRPI0506826A (ja) |
CA (1) | CA2553199C (ja) |
IL (1) | IL176783A (ja) |
NO (1) | NO20063444L (ja) |
NZ (1) | NZ548447A (ja) |
RU (1) | RU2388817C2 (ja) |
WO (1) | WO2005070136A2 (ja) |
ZA (1) | ZA200605716B (ja) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7465566B2 (en) | 2000-02-23 | 2008-12-16 | The Trustees Of The University Of Pennsylvania | Regulation of genes via application of specific and selective electrical and electromagnetic signals |
US7981611B2 (en) | 2000-02-23 | 2011-07-19 | The Trustees Of The University Of Pennsylvania | Regulation of fibroblastic growth factor-2 (FGF-2) gene expression in living cells with the application of specific and selective electric and electromagnetic fields |
US7465546B2 (en) * | 2000-02-23 | 2008-12-16 | The Trustees Of The University Of Pennsylvania | Regulation of transforming growth factor-beta (TGF-β) gene expression in living cells via the application of specific and selective electric and electromagnetic fields |
US7429471B2 (en) * | 2000-02-23 | 2008-09-30 | The Trustees Of The University Of Pennsylvania | Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals |
US8313908B2 (en) | 2000-02-23 | 2012-11-20 | The Trustees Of The University Of Pennsylvania | Regulation of stem cell gene production with specific and selective electric and electromagnetic fields |
US7130692B2 (en) | 2000-02-23 | 2006-10-31 | The Trustees Of The University Of Pennsylvania | Portable electrotherapy device for treating osteoarthritis and other diseases, defects and injuries of the knee joint |
US7022506B2 (en) | 2000-02-23 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee |
US7374916B2 (en) | 2000-02-23 | 2008-05-20 | The Trustees Of The University Of Pennsylvania | Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals |
WO2003004092A2 (en) | 2001-07-03 | 2003-01-16 | The Trustees Of The University Of Pennsylvania | Device and method for electrically inducing osteogenesis in the spine |
US7158835B2 (en) | 2001-12-21 | 2007-01-02 | The Trustees Of The University Of Pennsylvania | Device for treating osteoporosis, hip and spine fractures and fusions with electric fields |
JP2007511289A (ja) | 2003-11-14 | 2007-05-10 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | ヒトの股関節における変形性関節症、軟骨疾患、欠損症、および傷害の治療法および治療装置 |
US9656096B2 (en) | 2003-12-05 | 2017-05-23 | Rio Grande Neurosciences, Inc. | Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans |
US9415233B2 (en) | 2003-12-05 | 2016-08-16 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological pain |
US9433797B2 (en) | 2003-12-05 | 2016-09-06 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurodegenerative conditions |
US8961385B2 (en) | 2003-12-05 | 2015-02-24 | Ivivi Health Sciences, Llc | Devices and method for treatment of degenerative joint diseases with electromagnetic fields |
US10350428B2 (en) | 2014-11-04 | 2019-07-16 | Endonovo Therapetics, Inc. | Method and apparatus for electromagnetic treatment of living systems |
US9440089B2 (en) | 2003-12-05 | 2016-09-13 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke |
JP4801802B2 (ja) | 2004-01-12 | 2011-10-26 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 特定の選択的な電気信号および電磁信号によって生成される電場の印加を介して骨細胞における骨形成タンパク質(bmp)遺伝子発現を上方制御するシステムおよび方法 |
US8070703B2 (en) * | 2004-03-10 | 2011-12-06 | Vision Quest Industries Incorporated | Electrically stimulating orthotic device and segmented liner |
US8936560B2 (en) * | 2004-03-10 | 2015-01-20 | Vision Quest Industries Incorporated | Bracing and electrostimulation for arthritis |
US8454543B2 (en) | 2004-03-10 | 2013-06-04 | Vision Quest Industries Incorporated | Electrodes for orthotic device |
BRPI0509444A (pt) | 2004-04-19 | 2007-09-04 | Ivivi Technologies Inc | método para o tratamento eletromagnético de tecidos e células vivos através da intensificação da angiogênese e da neovascularização, aparelho de tratamento eletromagnético e dispositivo gerador de sinais eletromagnéticos |
US20080039901A1 (en) * | 2005-06-03 | 2008-02-14 | Kronberg James W | Methods for modulating chondrocyte proliferation using pulsing electric fields |
US7840272B2 (en) * | 2005-06-03 | 2010-11-23 | Medrelief Inc. | Methods for modulating osteochondral development using bioelectrical stimulation |
JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードrna転写物 |
US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
EP2259774B1 (en) | 2008-02-27 | 2012-12-12 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
MX339820B (es) | 2008-10-03 | 2016-06-13 | Curna Inc | Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1. |
US8612008B2 (en) * | 2008-10-23 | 2013-12-17 | Electromedical Products International, Inc. | Microcurrent and cranial electrotherapy stimulator for control of anxiety, insomnia, depression and pain |
JP6091752B2 (ja) | 2008-12-04 | 2017-03-08 | クルナ・インコーポレーテッド | Epoに対する天然アンチセンス転写物の抑制によるエリスロポエチン(epo)関連疾患の治療 |
RU2746478C2 (ru) | 2008-12-04 | 2021-04-14 | КьюРНА, Инк. | Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена |
RU2569182C2 (ru) | 2008-12-04 | 2015-11-20 | КьюРНА,Инк.,US | Лечение заболеваний, связанных с фактором роста эндотелия сосудов (vegf), посредством ингибирования природного антисмыслового транскрипта к vegf |
US9074210B2 (en) | 2009-02-12 | 2015-07-07 | Curna, Inc. | Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF |
WO2010107733A2 (en) | 2009-03-16 | 2010-09-23 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
CA2755404C (en) | 2009-03-17 | 2020-03-24 | Joseph Collard | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
JP6250930B2 (ja) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療 |
CN102459596B (zh) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
JP5931720B2 (ja) | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Dmdファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療 |
JP5922017B2 (ja) | 2009-05-18 | 2016-05-24 | クルナ・インコーポレーテッド | リプログラミング因子に対する天然アンチセンス転写物の抑制によるリプログラミング因子関連疾患の治療 |
US8895527B2 (en) | 2009-05-22 | 2014-11-25 | Curna, Inc. | Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 |
KR20120024819A (ko) | 2009-05-28 | 2012-03-14 | 오피케이오 큐알엔에이, 엘엘씨 | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료 |
ES2629339T3 (es) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1 |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
CN102597238B (zh) | 2009-06-24 | 2016-06-29 | 库尔纳公司 | 通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病 |
WO2010151674A2 (en) | 2009-06-26 | 2010-12-29 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
KR101801407B1 (ko) | 2009-07-24 | 2017-11-24 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료 |
WO2011017516A2 (en) | 2009-08-05 | 2011-02-10 | Curna, Inc. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
EP2464731B1 (en) | 2009-08-11 | 2016-10-05 | CuRNA, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
CA2771228C (en) | 2009-08-21 | 2020-12-29 | Opko Curna, Llc | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
CA2771172C (en) | 2009-08-25 | 2021-11-30 | Opko Curna, Llc | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
WO2011038210A2 (en) | 2009-09-25 | 2011-03-31 | Curna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
US9492584B2 (en) | 2009-11-25 | 2016-11-15 | Difusion Technologies, Inc. | Post-charging of zeolite doped plastics with antimicrobial metal ions |
EP2512538B1 (en) | 2009-12-11 | 2017-02-22 | Difusion Technologies, Inc. | Method of manufacturing antimicrobial implants of polyetheretherketone |
EP2513310B1 (en) | 2009-12-16 | 2017-11-01 | CuRNA, Inc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
WO2011079263A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
NO2516648T3 (ja) | 2009-12-23 | 2018-04-07 | ||
ES2585829T3 (es) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63 |
ES2657452T3 (es) | 2009-12-29 | 2018-03-05 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1 |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
DK2521784T3 (en) | 2010-01-04 | 2018-03-12 | Curna Inc | TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8 |
RU2612161C2 (ru) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы |
NO2524039T3 (ja) | 2010-01-11 | 2018-04-28 | ||
JP5981850B2 (ja) | 2010-01-25 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療 |
WO2011103528A2 (en) | 2010-02-22 | 2011-08-25 | Opko Curna Llc | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
CN102869777B (zh) | 2010-04-02 | 2018-11-02 | 库尔纳公司 | 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病 |
TWI644675B (zh) | 2010-04-09 | 2018-12-21 | 可娜公司 | 藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病 |
WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
MX2012012710A (es) | 2010-05-07 | 2013-02-26 | Difusion Technologies Inc | Implantes medicos con hidrofilicidad incrementada. |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
KR101857090B1 (ko) | 2010-05-26 | 2018-06-26 | 큐알엔에이, 인크. | 무조(無調)의 동소체 1 (atoh1)에 대한 자연 안티센스 전사체의 저해에 의한 atoh1 관련된 질환의 치료 |
US8980858B2 (en) | 2010-05-26 | 2015-03-17 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA |
SI2585596T1 (sl) | 2010-06-23 | 2021-05-31 | Curna, Inc. | Zdravljenje bolezni, povezanih z alfa podenoto (scna) napetostnega natrijevega kanala z inhibicijo naravne protismiselne rnk na scna |
DK2593547T3 (en) | 2010-07-14 | 2018-02-26 | Curna Inc | Treatment of Discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG |
EP2977054A1 (en) | 2010-09-03 | 2016-01-27 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
CA2813036A1 (en) | 2010-10-01 | 2012-04-05 | Ivivi Health Sciences, Llc | Method and apparatus for electromagnetic treatment of head, cerebral and neural injury in animals and humans |
US8993533B2 (en) | 2010-10-06 | 2015-03-31 | Curna, Inc. | Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
EP2630241B1 (en) | 2010-10-22 | 2018-10-17 | CuRNA, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
US8987225B2 (en) | 2010-11-23 | 2015-03-24 | Curna, Inc. | Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG |
WO2012170771A1 (en) | 2011-06-09 | 2012-12-13 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
WO2013016664A2 (en) | 2011-07-27 | 2013-01-31 | Vision Quest Industries Incorporated Dba Vq Orthocare | Electrostimulation system |
EP2753317B1 (en) | 2011-09-06 | 2020-02-26 | CuRNA, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
US8343027B1 (en) | 2012-01-30 | 2013-01-01 | Ivivi Health Sciences, Llc | Methods and devices for providing electromagnetic treatment in the presence of a metal-containing implant |
JP2015511494A (ja) | 2012-03-15 | 2015-04-20 | キュアナ,インク. | 脳由来神経栄養因子(bdnf)に対する天然アンチセンス転写物の阻害によるbdnf関連の疾患の処置 |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
WO2015161063A1 (en) | 2014-04-16 | 2015-10-22 | Iviv Health Sciences, Llc | A two-part pulsed electromagnetic field applicator for application of therapeutic energy |
WO2015187871A1 (en) * | 2014-06-03 | 2015-12-10 | Vomaris Innovations, Inc. | Methods and devices for modulating gene expression and enzyme activity |
US10806942B2 (en) | 2016-11-10 | 2020-10-20 | Qoravita LLC | System and method for applying a low frequency magnetic field to biological tissues |
US20210402052A1 (en) | 2020-06-30 | 2021-12-30 | Difusion, Inc. | Medical Implants And Methods Of Manufacture |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523271A (ja) * | 2000-02-23 | 2003-08-05 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 特異的且つ選択的な電気的及び電磁気的シグナルの施用による遺伝子の調節 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4442846A (en) | 1981-11-10 | 1984-04-17 | University Of Pennsylvania | Distributed port bone-piercing cathode for electrically stimulated osteogenesis |
US4506674A (en) | 1981-11-10 | 1985-03-26 | Trustees Of The University Of Pennsylvania | Method of stimulating osteogenesis with distributed port cathode |
US4430999A (en) | 1981-11-10 | 1984-02-14 | Trustees Of The University Of Pennsylvania | Osteogenesis stimulating cathode assembly for use with an internal fixation device |
US4509520A (en) | 1982-02-22 | 1985-04-09 | Biolectron, Inc. | Electrical stimulating apparatus |
US4549547A (en) | 1982-07-27 | 1985-10-29 | Trustees Of The University Of Pennsylvania | Implantable bone growth stimulator |
US4467809A (en) | 1982-09-17 | 1984-08-28 | Biolectron, Inc. | Method for non-invasive electrical stimulation of epiphyseal plate growth |
US4467808A (en) | 1982-09-17 | 1984-08-28 | Biolectron, Inc. | Method for preventing and treating osteoporosis in a living body by using electrical stimulation non-invasively |
US4487834A (en) | 1982-09-17 | 1984-12-11 | Biolectron, Inc. | Electrical stimulation of articular chondrocytes |
US5269746A (en) | 1982-12-20 | 1993-12-14 | Jacobson Jerry I | Therapeutic treatment of mammals for epilepsy and Parkinson's disease |
US4535775A (en) | 1983-02-10 | 1985-08-20 | Biolectron, Inc. | Method for treatment of non-union bone fractures by non-invasive electrical stimulation |
IT1159024B (it) | 1983-06-02 | 1987-02-25 | Ruggero Cadossi | Metodo e dispositivo per il trattamento di tessuti e cellule viventi mediante campi elettromagnetici pulsanti |
US4600010A (en) | 1984-10-04 | 1986-07-15 | Biolectron, Inc. | Electric stimulator and test instrument therefor |
US5014699A (en) * | 1986-05-23 | 1991-05-14 | Trustees Of The University Of Pennsylvania | Electromagnetic method and apparatus for healing living tissue |
US6120502A (en) | 1988-06-13 | 2000-09-19 | Michelson; Gary Karlin | Apparatus and method for the delivery of electrical current for interbody spinal arthrodesis |
US5038797A (en) | 1990-02-20 | 1991-08-13 | Romaine, Incorporated | Electrical stimulation treatment device and method of use |
US5273033A (en) | 1991-09-19 | 1993-12-28 | Murray Electronics Associates Limited Partnership | Electrical stimulation for treatment of osteoarthritis |
US5338286A (en) | 1992-12-08 | 1994-08-16 | Electro-Biology, Inc. | Electromagnetic bioresponse by selective spectral suppression in pulsed field stimulation |
US5374283A (en) | 1993-12-01 | 1994-12-20 | Flick; A. Bart | Electrical therapeutic apparatus |
US5743844A (en) | 1996-11-01 | 1998-04-28 | Amei Technologies, Inc. | High efficiency pulsed electromagnetic field (PEMF) stimulation therapy method and system |
US6132362A (en) | 1996-11-01 | 2000-10-17 | Amei Technologies, Inc. | Pulsed electromagnetic field (PEMF) stimulation therapy system with bi-phasic coil |
US6261221B1 (en) | 1996-11-01 | 2001-07-17 | Amei Technologies Inc. | Flexible coil pulsed electromagnetic field (PEMF) stimulation therapy system |
US5968527A (en) | 1997-02-27 | 1999-10-19 | Catholic University Of America, The | Protection of living systems from the adverse effects of stress |
US6083149A (en) | 1997-10-22 | 2000-07-04 | Emf Therapeutics, Inc. | Magnetic field device and method for inhibiting angiogenesis and retarding growth rates of tumors in mammals |
US6186940B1 (en) | 1998-05-18 | 2001-02-13 | Robert N. Kirschbaum | Energized trace elements |
RU2147895C1 (ru) | 1999-01-05 | 2000-04-27 | Корж Геннадий Михайлович | Способ лечения неосложненных переломов нижней челюсти |
US6292699B1 (en) | 1999-01-29 | 2001-09-18 | Electro-Biology, Inc. | Direct current stimulation of spinal interbody fixation device |
WO2000066068A2 (en) | 1999-04-29 | 2000-11-09 | North Shore Long Island Jewish Research Corporation | Method for inducing growth and enhancing survival of nervous tissue |
US6923784B2 (en) | 1999-04-30 | 2005-08-02 | Medtronic, Inc. | Therapeutic treatment of disorders based on timing information |
DE19933719A1 (de) | 1999-07-19 | 2001-01-25 | Medigene Ag | Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung |
US7022506B2 (en) | 2000-02-23 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee |
US7374916B2 (en) | 2000-02-23 | 2008-05-20 | The Trustees Of The University Of Pennsylvania | Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals |
US7130692B2 (en) * | 2000-02-23 | 2006-10-31 | The Trustees Of The University Of Pennsylvania | Portable electrotherapy device for treating osteoarthritis and other diseases, defects and injuries of the knee joint |
US7465546B2 (en) * | 2000-02-23 | 2008-12-16 | The Trustees Of The University Of Pennsylvania | Regulation of transforming growth factor-beta (TGF-β) gene expression in living cells via the application of specific and selective electric and electromagnetic fields |
US7429471B2 (en) | 2000-02-23 | 2008-09-30 | The Trustees Of The University Of Pennsylvania | Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals |
US6485963B1 (en) | 2000-06-02 | 2002-11-26 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Growth stimulation of biological cells and tissue by electromagnetic fields and uses thereof |
WO2002035985A2 (en) | 2000-11-02 | 2002-05-10 | March Keith L | Method and system for modulation of oscillating signals to enhance biologic effects |
US20050049640A1 (en) | 2003-05-12 | 2005-03-03 | Gurtner Geoffrey C. | Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of FGF-2 |
JP2007511289A (ja) * | 2003-11-14 | 2007-05-10 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | ヒトの股関節における変形性関節症、軟骨疾患、欠損症、および傷害の治療法および治療装置 |
JP4801802B2 (ja) | 2004-01-12 | 2011-10-26 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 特定の選択的な電気信号および電磁信号によって生成される電場の印加を介して骨細胞における骨形成タンパク質(bmp)遺伝子発現を上方制御するシステムおよび方法 |
-
2005
- 2005-01-11 JP JP2006549515A patent/JP4801802B2/ja not_active Expired - Lifetime
- 2005-01-11 CA CA2553199A patent/CA2553199C/en not_active Expired - Lifetime
- 2005-01-11 BR BRPI0506826-6A patent/BRPI0506826A/pt not_active Application Discontinuation
- 2005-01-11 CN CN2005800047115A patent/CN1918285B/zh not_active Expired - Fee Related
- 2005-01-11 RU RU2006129306/13A patent/RU2388817C2/ru not_active IP Right Cessation
- 2005-01-11 KR KR1020067013999A patent/KR101324824B1/ko active IP Right Grant
- 2005-01-11 AU AU2005206794A patent/AU2005206794B2/en not_active Expired
- 2005-01-11 WO PCT/US2005/000793 patent/WO2005070136A2/en active Application Filing
- 2005-01-11 NZ NZ548447A patent/NZ548447A/en not_active IP Right Cessation
- 2005-01-11 EP EP05705445A patent/EP1716228A4/en not_active Ceased
- 2005-01-11 US US10/585,718 patent/US8017369B2/en not_active Expired - Lifetime
-
2006
- 2006-07-11 ZA ZA200605716A patent/ZA200605716B/xx unknown
- 2006-07-11 IL IL176783A patent/IL176783A/en active IP Right Grant
- 2006-07-26 NO NO20063444A patent/NO20063444L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523271A (ja) * | 2000-02-23 | 2003-08-05 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 特異的且つ選択的な電気的及び電磁気的シグナルの施用による遺伝子の調節 |
Also Published As
Publication number | Publication date |
---|---|
US8017369B2 (en) | 2011-09-13 |
CN1918285B (zh) | 2013-09-25 |
EP1716228A2 (en) | 2006-11-02 |
US20070299472A1 (en) | 2007-12-27 |
AU2005206794B2 (en) | 2010-09-16 |
WO2005070136A2 (en) | 2005-08-04 |
NO20063444L (no) | 2006-10-10 |
CA2553199A1 (en) | 2005-08-04 |
JP2007517624A (ja) | 2007-07-05 |
ZA200605716B (en) | 2008-11-26 |
KR20060129256A (ko) | 2006-12-15 |
CA2553199C (en) | 2014-03-25 |
IL176783A (en) | 2014-05-28 |
BRPI0506826A (pt) | 2007-05-29 |
EP1716228A4 (en) | 2009-06-17 |
WO2005070136A3 (en) | 2005-10-06 |
NZ548447A (en) | 2010-04-30 |
RU2388817C2 (ru) | 2010-05-10 |
IL176783A0 (en) | 2006-10-31 |
CN1918285A (zh) | 2007-02-21 |
RU2006129306A (ru) | 2008-02-20 |
KR101324824B1 (ko) | 2013-11-01 |
AU2005206794A1 (en) | 2005-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4801802B2 (ja) | 特定の選択的な電気信号および電磁信号によって生成される電場の印加を介して骨細胞における骨形成タンパク質(bmp)遺伝子発現を上方制御するシステムおよび方法 | |
JP4455801B2 (ja) | 特異的且つ選択的な電気的及び電磁気的シグナルの施用による遺伝子の調節 | |
AU2007255038B2 (en) | Regulation of transforming growth factor-beta (TGF-beta) gene expression in living cells via the application of specific and selective electric and electromagnetic fields | |
US20040073260A1 (en) | Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals | |
CA2529374C (en) | Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals | |
JP4344321B2 (ja) | 特異的で選択的な電気シグナル及び電磁シグナルを用いたアグリカン遺伝子発現の制御方法 | |
JP5596563B2 (ja) | 特異的且つ選択的な電場および電磁場の印加を使用した生体細胞における線維芽成長因子−2(fgf−2)遺伝子発現の制御 | |
MXPA06007918A (en) | Up-regulation of bone morphogenetic protein (bmp) gene expression in bone cells by electromagnetic signals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080111 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100818 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110414 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110613 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110712 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110806 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140812 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4801802 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |